PMID- 18356826 OWN - NLM STAT- MEDLINE DCOM- 20080908 LR - 20131121 IS - 1930-7381 (Print) IS - 1930-7381 (Linking) VI - 16 IP - 6 DP - 2008 Jun TI - Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue. PG - 1199-207 LID - 10.1038/oby.2008.62 [doi] AB - OBJECTIVE: This study was designed to examine the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) ligands on the inflammatory changes induced by the interaction between adipocytes and macrophages in obese adipose tissue. METHODS AND PROCEDURES: PPAR-alpha ligands (Wy-14,643 and fenofibrate) were added to 3T3-L1 adipocytes, RAW264 macrophages, or co-culture of 3T3-L1 adipocytes and RAW264 macrophages in vitro, and monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-alpha) mRNA expression and secretion were examined. PPAR-alpha ligands were administered to genetically obese ob/ob mice for 2 weeks. Moreover, the effect of PPAR-alpha ligands was also evaluated in the adipose tissue explants and peritoneal macrophages obtained from PPAR-alpha-deficient mice. RESULTS: In the co-culture of 3T3-L1 adipocytes and RAW264 macrophages, PPAR-alpha ligands reduced MCP-1 and TNF-alpha mRNA expression and secretion in vitro relative to vehicle-treated group. The anti-inflammatory effect of Wy-14,643 was observed in adipocytes treated with macrophage-conditioned media or mouse recombinant TNF-alpha and in macrophages treated with adipocyte-conditioned media or palmitate. Systemic administration of PPAR-alpha ligands inhibited the inflammatory changes in adipose tissue from ob/ob mice. Wy-14,643 also exerted an anti-inflammatory effect in the adipose tissue explants but not in peritoneal macrophages obtained from PPAR-alpha-deficient mice. DISCUSSION: This study provides evidence for the anti-inflammatory effect of PPAR-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue, thereby improving the dysregulation of adipocytokine production and obesity-related metabolic syndrome. FAU - Toyoda, Takuya AU - Toyoda T AD - Department of Molecular Medicine and Metabolism, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan. FAU - Kamei, Yasutomi AU - Kamei Y FAU - Kato, Hirotsugu AU - Kato H FAU - Sugita, Satoshi AU - Sugita S FAU - Takeya, Motohiro AU - Takeya M FAU - Suganami, Takayoshi AU - Suganami T FAU - Ogawa, Yoshihiro AU - Ogawa Y LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20080320 PL - United States TA - Obesity (Silver Spring) JT - Obesity (Silver Spring, Md.) JID - 101264860 RN - 0 (Anti-Inflammatory Agents) RN - 0 (Ccl2 protein, mouse) RN - 0 (Chemokine CCL2) RN - 0 (Ligands) RN - 0 (PPAR alpha) RN - 0 (Pyrimidines) RN - 0 (RNA, Messenger) RN - 0 (Tumor Necrosis Factor-alpha) RN - 86C4MRT55A (pirinixic acid) RN - U202363UOS (Fenofibrate) SB - IM MH - 3T3-L1 Cells MH - Adipocytes/*drug effects/metabolism/pathology MH - Animals MH - Anti-Inflammatory Agents/pharmacology MH - Cell Communication/*drug effects MH - Cell Line MH - Chemokine CCL2/metabolism MH - Coculture Techniques MH - Disease Models, Animal MH - Fenofibrate/*pharmacology MH - Ligands MH - Macrophages/*drug effects/metabolism/pathology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Mice, Knockout MH - Mice, Obese MH - Obesity/*metabolism/pathology MH - PPAR alpha/genetics/*metabolism MH - Peritoneal Cavity/pathology MH - Pyrimidines/*pharmacology MH - RNA, Messenger/metabolism MH - Tumor Necrosis Factor-alpha/metabolism EDAT- 2008/03/22 09:00 MHDA- 2008/09/09 09:00 CRDT- 2008/03/22 09:00 PHST- 2008/03/22 09:00 [pubmed] PHST- 2008/09/09 09:00 [medline] PHST- 2008/03/22 09:00 [entrez] AID - oby200862 [pii] AID - 10.1038/oby.2008.62 [doi] PST - ppublish SO - Obesity (Silver Spring). 2008 Jun;16(6):1199-207. doi: 10.1038/oby.2008.62. Epub 2008 Mar 20.